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Abstract 
Cardiac tyhrotropin-releasing hormone (TRH) is overexpressed in the 
hypertrophied left ventricle (LV) of spontaneously hypertensive rats (SHR) and its 
inhibition prevents both hypertrophy and fibrosis. In a normal heart, the TRH 
increase induces fibrosis and hypertrophy opening the question of whether TRH 
could be a common mediator of left ventricular hypertrophy (LVH). We used 
angiotensin II (AngII) as an inductor of LVH to evaluate if the blockade of LV-TRH  
prevents hypertrophy and fibrosis in mice. We challenged C57BL/6 adult male 
mice with an infusion of  AngII (osmotic pumps; 2 mg/kg.day) to induce LVH. 
Groups of mice were injected with an intracardiac siRNA-TRH or scrambled siRNA 
(siRNA-Con). Body weight, water intake and systolic arterial blood pressure 
(SABP) were measured daily. AngII significantly increased water intake and SABP 
(p<0.05). Cardiac hypertrophy (heart weight/body weight) was evident in the group 
with the normal cardiac TRH system. In fact, it was found an AngII-induced 
increase of TRH precursor mRNA (p<0.05) in conjunction with elevated TRH levels 
measured by immunohistochemistry and western blot. These changes were not 
observed in the AngII + siRNA-TRH group. Furthermore, AngII increased 
significantly (p<0.05) BNP (hypertrophic marker), collagens I and III and TGF-β 
(fibrosis markers) expression in the group with the native cardiac TRH system. 
These increases were attenuated in the groups with the TRH system blocked 
despite the high blood pressure.  Similar and stronger results were observed “in 
vitro” with NIH3T3 and H9C2 cell culture models, where, when the TRH system is 
blocked, AngII stimulus was not able to induce the markers of its fibrotic and 
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hypertrophic effects, so we believe that these effects are independent of any other 
physiological modifications. 
Our results point out that cardiac TRH is required for AngII-induced hypertrophic 
and fibrotic effects. 
 
Keywords: Cardiac hypertrophy, TRH, thyroliberin, Angiotensin II, Mice,  H9C2,  
NHI3T3, siRNA.    
 
Non standard abbreviations: AngII angiotensin II,  LV left ventricle, LVH left 
ventricular hypertrophy, siRNA small interference RNA.    
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1. Introduction 
The renin–angiotensin system has been strongly implicated in hypertension and its 
complications, and, it has been suggested that the mechanisms by which 
angiotensin II (AngII) raise blood pressure may be different from those involved in 
the cardiovascular remodeling and end-organ damage [1]. Indeed, many 
downstream signaling cascades and target genes/proteins of Ang II have been 
identified, although cardiac effects such as  hypertrophy and fibrosis, independent 
of blood pressure, remains largely unclear [2,3].  
Based on the fact that more than 70% of the Thyrotropin Releasing Hormone 
(TRH) is produced in extra hypothalamic areas and had been found in cardiac 
tissue, we have investigated and reported that the spontaneously hypertensive 
adult rat (SHR) shows left ventricular (LV) TRH hyperactivity, and its long-term 
inhibition prevents fibrosis and cardiomyocyte enlargement [4]. These results 
suggested that the cardiac TRH system participates in the development of 
hypertrophy. In addition, LV overexpression of TRH induces some features of the 
hypertrophied heart in healthy Wistar rat [5], showing an active role of TRH in 
cardiac hypertrophy. 
Data from other laboratory indicated that the primary source of preproTRH in the 
heart were fibroblasts [6], and less expression was observed in cardiomyocytes. 
We confirmed these results and described that cardiomyocytes and fibroblasts 
stimulated with exogenous TRH induced hypertrophic and fibrotic markers [5]. 
Moreover, the specific type 1 TRH receptor was also found in the heart [7] and 
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belongs to the G protein family [8], which includes the AngII receptor type 1 (Agtr1) 
and the endothelin receptor type a, both inducers of hypertrophy and fibroblast 
proliferation. 
In addition, Jankowski et al proposed a hypothetical mechanism of TRH-mediated 
hypertrophy by which the stimulation of cardiac TRH receptors enhances fibroblast 
proliferation and secretion, and simultaneously cardiomyocyte hypertrophy [9]. 
Since then, the question of whether cardiac TRH is a common mediator of both 
fibrosis and hypertrophy has not been elucidated. On this line of thought we 
propose that LV hypertrophy and fibrosis induced by AngII is mediated by the 
cardiac TRH system and we speculate that the specific LV TRH inhibition will 
attenuate fibrosis and/or hypertrophy induced by AngII in C57 mice, despite the 
high blood pressure. 
Therefore, the aim of the present study was to demonstrate that AngII-induced 
cardiac effects, including fibrosis and hypertrophy are mediated by LV TRH and  if 
its cardiac inhibition attenuates heart damage.  
 
2. Methods 
2.1 Ethics Statement 
The Institutional Animal Care and Use Committee approved the animal 
experimentation protocols following the Ethical Guidelines. The protocol was 
approved by the CICUAL Instituto de investigaciones Médicas (IDIM) UBA-
CONICET, Buenos Aires University (UBA) Argentina (Res Nº 2331; November 8, 
2011). All manoeuvres were performed under anaesthesia i.p. (unique dose) 
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ketamine (90 mg/kg) and xylasine (10 mg/kg), and all efforts were made to 
minimize animal suffering following the NHI Ethical Guidelines.                        
C57BL/6 male mice were housed in a room with controlled temperature (23±1C) 
under a 12-hour light/dark schedule. 
 
2.2 In vivo treatment 
We performed two consecutive protocols exposing mice to a 7-day and 14-day 
continuous infusion of AngII (2 mg kg−1 d−1), a concentration known to establish 
chronic hypertension and cardiac hypertrophy [10, 11]. In addition, subgroups of 
AngII-treated animals were assigned in a random blind fashion to one of the two 
subgroups as follows: specific TRH-siRNA or scramble Con-siRNA (n=8 per 
group), and were anesthetized (ketamine, 90 mg/kg; xylasine, 10 mg/kg).  SiRNA 
intra-cardiac injections were conducted simultaneously with the osmotic pump 
(ALZET®) implanted dorsally to maintain the knockdown effect during all the 
experiment as previously described [4]. All injections were administered under 
echography. A unique injection of fifty ul of siRNA (10 μg) or saline was injected in 
the left ventricle (LV) wall. The probe was aligned with the needle and special care 
was taken to see the region of the myocardial wall. SiRNA oligonucleotides were 
dissolved in saline. One injection was enough to maintain the knockdown effect 
during the experiment (14 days).  All experiments were performed blindly with 
respect to the treatment. 
Body weight, systolic arterial blood pressure (SABP) and water intake were 
recorded during the experiments. 
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2.3 SABP measurement: 
SABP was measured by determining the tail blood volume with a volume pressure 
recording sensor and an occlusion tail-cuff (CODA; Kent Scientific, Torrington, CT). 
Prior to this, the animals were put in a quiet room for 30 min before the 
measurement of SABP and heart rate. Each value corresponds to at least three 
independent measurements.  
 
2.4 Tissue samples: 
Animals were euthanized by decapitation; the hearts were rapidly removed and 
processed according to the protocol for peptide and mRNA determinations. Blood 
samples were collected for thyroid hormone and TSH measurements. 
 
2.5 Gene expression quantifications: 
Total RNA was extracted from cardiac tissue. Gene expression quantifications 
were performed using a real-time RT-PCR technique normalized by a 
housekeeping gene (β-actin) expression. Briefly, for cDNA synthesis, 1 μg of total 
RNA and 1 μg of random hexamer primers (Promega Corp, WI, USA) were heated 
followed by incubation at 4°C. After adding 5 L of M-MLV RT 5X buffer (250 
mmol/L Tris-HCl, pH 8.3, 375 mmol/L KCl, 15 mmol/L MgCl2, 50 mmol/L DTT), 25 
U RNasin (Promega Corp, WI, USA), 1.25 L of 10 mmol/L dNTPs (Invitrogen, CA, 
USA), and 200 U of MMLV-reverse transcriptase (Promega Corp, WI, USA), the 
reaction was carried out at 37ºC for 1 h, followed by inactivation of the enzyme at 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
95ºC for 10 min. Real-time PCR was performed using a BioRad iQ iCycler 
Detection System (BioRad Laboratories, Ltd., CA, USA) with SYBER green 
fluorophore. Reactions (duplicates) were carried out in a total volume of 20 L. A 
three-step protocol (95°C for 30 sec, 62°C annealing for 30 sec, 72°C for 40 sec) 
was repeated for 40 cycles. 
A melt curve analysis was performed after every run to ensure a single amplified 
product for every reaction. The size of the amplicons generated was confirmed on 
a 2% agarose gel. In accordance with the literature, we did not find any differences 
between experimental groups in the β-actin housekeeping gene by the GeNorm 
software. Quantification was performed by normalizing Ct (cycle threshold) values 
with β-Act Ct and analyzed with the 2−ΔΔCT method. 
Mouse primers were from Invitrogen, (Invitrogen, CA, USA), listed in 
supplementary file.  
 
2.6 Pathology examination 
Mice hearts were perfuse with saline solution through the abdominal aorta until 
they were free of blood. Tissue was fixed in phosphate-buffered saline (PBS) 10% 
formaldehyde (pH 7.2) and embedded in paraffin. Three-micron sections were cut 
and stained with haematoxylin-eosin (H&E), Masson’s trichrome and Sirius red.  
The image analysis technique was carried out on ten microscopic fields at a 
magnification of 400x scanned in the form of Greek guard. All observations in light 
microscopy were performed using a Nikon E400 light microscope (Nikon 
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Instrument Group, Melville, N.Y., USA), and the observer was blind to the animal 
group. 
 
2.7 Immunohistochemical evaluation 
Immunolabelling was carried out using a modified avidin-biotin-peroxidase 
technique (Vectastain ABC kit, Universal Elite; Vector Laboratories, California, 
USA). Following deparaffinization and rehydration, the sections were washed in 
PBS for 5 min. Quenching of endogenous peroxidase activity was achieved by 
incubating the sections for 30 min in 1% hydrogen peroxide in methanol. After 
washing in PBS (pH 7.2) for 20 min, the sections were incubated with blocking 
serum for a further 20 min. Thereafter, the sections were rinsed in PBS and 
incubated with biotinylated universal antibody for 30 min. After a final wash in PBS, 
the sections were incubated for 40 min with Vectastain Elite ABC reagent (Vector 
Laboratories, California, USA) and exposed for 5 min to 0.1% diaminobenzidine 
(Polyscience, Warrington, Pennsylvania, USA) and 0.2% hydrogen peroxide in 50 
mmol/L Tris buffer (pH 8). For the purpose of evaluating TRH content by 
immunohistochemestry, the specific anti-rat/mouse TRH polyclonal antibody was 
used at a dilution of 1:100 (sc-366754, Santa Cruz, Inc., USA), for TGF-β1 a 
polyclonal antibody was used at a dilution of 1:300 (sc-146, Santa Cruz, Inc., USA) 
and for collagen type I a rabbit polyclonal antibody was used at a dilution 1:100 
(ab34710, Abcam, Cambridge, MA). For the evaluation of alpha-actin content,  the 
alpha-cardiac actin (Alpha Sr-1): sc-58671 Santa Cruz Biotech mouse monoclonal 
antibody was used  at  a dilution 1:100 (images 600x) and for myosin evaluation 
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the myosin heavy chain (MYH7)  (A4.951) sc-53090 Santa Cruz Biotech mouse 
monoclonal antibody was used at a dilution 1:100 (images 600x). 
 
 
2.8 Cell culture 
Rat cardiomyoblasts (H9c2) (ATCC) were seeded (1×104 cells/cm2) and cultured in 
Dulbecco's modified Eagle's medium (DMEM-F12) supplemented with 10% fetal 
bovine serum (FBS), 50   μg/mL penicillin, and 50  μg/mL streptomycin and 
Fungizone (GIBCO) (250 μg/mL) under a normal culture condition (5% CO2, 37°C). 
Twenty-four hours before treatment, we switched to the differentiation medium 
(DMEM-F12; 1% FBS and 50  nM trans-retinoic acid RA, R2625; Sigma). 
Mouse fibroblasts (NIH3T3) were obtained from the ATCC and cultured in DMEM-
F12 supplemented with 5% FBS, 50   μg/mL penicillin, and 50  μg/mL 
streptomycin and Fungizone (GIBCO) (250 μg/mL) under a normal culture 
condition (5% CO2, 37°C). Twenty-four hours before treatment, cells were switched 
to DMEM-F12 without FBS. 
Transfection of cardiac cells was performed using Lipofectamine 2000 (Invitrogen) 
based on the manufacturer’s recommendations. For optimization of the procedure, 
the ratios of Lipofectamine to siRNA concentration (ul/ug) were selected to get the 
best result (4/1).  
 
2.9 Immunofluorescence 
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Cells was fixed with 4% formaldehyde for 20  min, washed with PBS (2 times), 
blocked with 3% FBS for 30 min at room temperature, and then incubated with 
primary antibodies, anti-TRH (SC-366754, 1/500) or anti-TGF-β1 (SC-146, 1/300) 
(Santa Cruz, Inc., USA) overnight at 4°C. After washing with PBS, they were 
incubated with the secondary antibody, Alexa Fluor 568 anti-rabbit (A10042) and 
Alexa Fluor 546 anti-mouse (A10036) (Invitrogen, Inc., USA), for 1  h at room 
temperature. Those samples were rinsed again with PBS and mounted in a 
mounting medium, with DNA-specific 4′,6-diamidino-2-phenylindole (DAPI; H1200; 
Vector Lab.) treatment. Fluorescence was observed using a confocal laser 
scanning microscope. 
 
2.10 Morphological and quantitative analysis 
All tissue samples were evaluated independently by two investigators without 
knowing the group to which the sample belonged. All measurements were carried 
out using an image analyser, Image-Pro Plus version 4.5 for Windows (Media 
Cybernetics, LP, Silver Spring, Maryland, USA). 
 
2.11 Biochemical and pathology studies 
At the end of the treatment, mice were weighed, and the snout-tail long index was 
measured before the animals were sacrificed by decapitation. Blood samples were 
collected with sodium EDTA, and thyroid hormone levels were measured using an 
enzyme immunometric assay (EIA) (Assay Designs, Inc., USA). Hearts were 
rapidly removed and weighed. In some animals, cardiac tissues were separated 
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(atria, left ventricle, right ventricle, and septum) for protein and mRNA 
quantification; others were used for pathology studies. 
 
2.12 Western Blot 
Left ventricular tissue was homogenized in RIPA lysis buffer (50 m M Tris-HCl, pH 
7.4, 150 mM NaCl, NP-40 1%, SDS 0,1% (W/V), Sodium Deoxicholate 0.5% 
(W/V)) with protease inhibitors (2ug/ml aprotinin, 7,5 μg/ml leupeptin, PMSF 1mM 
and EDTA 5mM). Total protein concentration was measured using Bradford assay. 
Subsequently, 40 μg of total protein from each sample was added to loading buffer 
(4% SDS, 10% 2-mercaptoethanol, 20% glicerol, 0,004% bromophenol blue, 0,125 
M Tris-HCl), and was resolved by SDS-12% PAGE and electro blotted onto PVDF 
membranes (Thermo Scientific, Rockford, USA). After blocking for 1 h in TBST 
containing 5% non-fat milk, membranes were probed with a rabbit anti TRH 
precursor (Abcam, Cambridge, MA, USA, 1:1000, ab171958) or a TGF-β1 antibody 
(Santa Cruz Biotechnology Inc., USA, 1:100, sc-146) at 4 °C overnight and were 
washed three times in TBST. Then, membranes were incubated with goat anti-
rabbit lgG peroxidase conjugated antibody (Santa Cruz Biotechnology, 1:3000 sc-
2004) and bands were visualized by  chemiluminescence (Clarity ™ ECL 
Substrate, Bio-RAD Laboratories, Florida, USA) according to the manufacturer's 
instructions and exposured to x-ray films (Carestream Healt inc, Rochester, NY, 
USA). The housekeeping gene β-Actin (Abcam, Cambridge, MA, USA 1:1500, 
ab6276) was used as load control. For quantification, we used Image-Studio Lite 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
software 5.2 version (Li-cor Biotechnology, Lincoln, NE, USA). The relative level of 
protein expression was expressed as the ratio to β-Actin.  
 
2.12 Statistics 
Values are expressed as mean ± standard error of the mean (SEM). All statistical 
analyses were performed using absolute values and processed using Statistics, 
version 6.0 (Software, Inc., California, USA). The assumption test to determine 
Gaussian distribution was performed using the Kolmogorov-Smirnov method. For 
parameters with Gaussian distribution, comparisons between groups were carried 
out using one-way analysis of variance (ANOVA) followed by Fisher test. In the 
case of two groups, comparison was performed using t-test or Mann-Whitney test 
when appropriate. A p value of less than 0.05 was considered significant. 
 
3. Results 
3.1 Efficacy of the Ang II infusion on blood pressure, daily water intake and 
body weight.  
As expected, Ang II infusion was able to increase blood pressure (panel A) and 
daily water intake (panel B) as its values were significantly higher in the Ang II 
groups evidencing the dipsogenic and hypertensive effect of the octapeptide, in an 
independent manner to the siRNA treatment. As shown in panel c, body weight 
was higher in all the treated groups and shows the expected increase after two 
weeks with respect to the basal group, without differences in the Ang II groups. 
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3.2 One week of AngII infusion induces a slight increase of left ventricle TRH 
precursor without changes in hypertrophic index. 
After one week, as shown in figure 2 panel A, we observed a slight left ventricle 
TRH increase that was accompanied by minor increases in fibrotic and 
hypertrophic markers gene expressions (panels B and C). When we analyzed the 
hypertrophic index between the groups, we unexpectedly did not find any changes 
between groups. This shows that although modest molecular alterations were 
observed, macroscopic damage was not evident. Assuming that this result could 
be due to the short duration of the treatment, we decided to challenge the animals 
with a longer AngII infusion (up to 14 days). 
 
3.3 Long-term AngII infusion requires an intact left ventricle TRH system to 
induce LVH.  
In line with our assumption, as shown in figure 3 panel A, we found a significant 
increase in the hypertrophic index that was only evident in the group treated with 
AngII with an active TRH system. Conversely, this increase was not seen in the 
group infused with AngII but with the TRH system blocked, which presented an 
index similar to the control group even in the presence of high SABP. Moreover, 
when we evaluated cardiomyocytes diameter in these animals we found a 
significant increase in Ang II group with a native TRH system and as expected this 
cardiomyocyte diameter increase was significantly attenuated in the group 
receiving Ang II with the TRH system blocked. 
Figure 3, panel B shows that the 14-days AngII infusion induced a more than 10-
fold increase in the preTRH gene expression (AngII+siRNA-CON), evident only in 
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the subgroup with a native TRH system compared with the control and AII+siRNA-
TRH groups, demonstrating the tripeptide induction by AngII and the efficacy of the 
long-lasting effect of the TRH inhibition manoeuvre. We confirmed this result by the 
measurement of TRH precursor by western blot where we found that the increase 
of TRH induced by Ang II was completely reversed in the group in which the TRH 
system was inhibit. 
In association with higher TRH expression, the long-term  AngII infusion induced 
significant increases in both hypertrophic, (β-MHC and BNP) (panel C), and  
fibrotic, (TGF-β1 and collagen  types III and I), recognized markers being stronger 
in the last ones (Figure 3 panel D and E respectively). These increases were seen 
in the subgroup with a functional TRH system (AII+siRNA-Con). On the contrary, 
hypertrophy and fibrosis markers gene expressions were highly attenuated when 
the TRH system was inhibited, as were similar to those in control groups. As 
changes in gene expression might not reflect protein status, we first performed 
western blot and found TGF- β1 induction by Ang II (around 100%); this increase 
was significantly reduced in the siRNA TRH treated group. We also performed 
immunohistochemistry for both peptides TRH precursor and TGF- β1 as shown in 
Figure 4 (panel A).  AngII infusion markedly induced TRH precursor expression, 
showing a brown immunohistochemical staining in the AngII group with a functional 
TRH system that was reduced to the 50% in the group with the TRH system 
blocked. TRH stain was not significant in the control group (left). A similar pattern 
was found for TGF-β1 (right). In fact, AngII-induction of TGF-β1 protein was 3 
folds- higher in the group with a functional TRH system, and was significantly 
decreased in the group with a blocked TRH system, although did not reach control 
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values. As shown in Figure 4 (panel B), we observed the stimulation of  collagens 
in the extracellular matrix (Sirius Red , left) that correlates with the significant 
increase observed in collagen type I (right) by AngII,  maximal in the group with 
AngII with an active TRH system. Moreover we observed approximately a 50% 
decrease in both signals in the AngII-treated group with the TRH system inhibited. 
The evaluation of Masson’s Trichrome staining showed a similar pattern 
(supplemental section) pointing out that the TRH system is necessary for long- 
term AngII full fibrotic effects. 
We evaluated two proteins strongly related with hypertrophy development, 
particularly α-cardiac actin and myosin heavy chain. As shown in figure 4 panel C 
we found that AngII treatment induced both protein, the inhibition of the TRH 
system significantly attenuated these increases, although did not  reverse them 
completely; this confirm the data obtained in cardiomyocyte diameter. 
 
3.4 Effect of the TRH inhibition on the fibrosis induced by AngII in the NIH3T3 
fibroblasts cell line. 
Considering that the heart is composed of several cell types, we decided to 
evaluate the effect of TRH inhibition on AngII treatment in two cell lines, mouse 
fibroblasts (NIH3T3) and rat cardiomyocytes (H9C2). Both cell lines have been 
studied for many years as models of cardiac cells and have been well 
characterized and validated [12]. 
First, we studied NIH-3T3 fibroblasts and, we confirmed the TRH induction by 
AngII (1uM) by immunofluorescence showing a strong sparkling signal in the cells 
stimulated by AngII with the native TRH system intact in contrast with the cells 
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incubated with saline, which presents a very low signal ( Figure 5, panel A). The 
AngII stimulus induces not only a significant increase in TRH peptide content but 
also markedly increases of the TGF-β1 and collagen types I and III gene 
expressions (panel B). To answer the question as to whether the increase of all the 
fibrotic markers, TGF-β1 and collagens, may be a consequence of TRH induction 
induced by the AngII stimulus, we evaluated the effect of AngII along with TRH 
inhibition over these markers. In agreement with in vivo experiments, siRNA-TRH 
treatment was effective in inhibiting TRH expression.  AngII stimulus only 
increased TRH in the group carrying the native TRH system and no increase was 
observed in the fibroblasts stimulated with AngII with the inhibited TRH system, in 
which TRH expression was similar to control cells. Thus, when the TRH system is 
blocked, AngII stimulus was not able to induce its fibrotic effect, and neither did 
TGF-β1 nor collagens type I and III change their expression 24 hours after AngII 
stimulus (Figure 5, panel C). Finally, we confirmed that the AngII induction over 
TRH expression was mostly mediated by its specific receptor, Agtr1, being that the 
losartan (LST) antagonist before to AngII hampers the TRH induction (Figure 5, 
panel D). 
 
3.5 Effect of the TRH inhibition on the hypertrophy induced by AngII in H9C2 
cardiomyocytes cell line. 
Secondly, we used cultured cardiomyocytes (H9C2 cells) and confirmed that AngII 
increased the TRH (peptide) content by immunofluorescence, showing a strong 
sparkling red signal in the cells stimulated by AngII with the native TRH system 
intact in contrast with the cells incubated with saline, which presents a very low 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
signal. Thereby, Figure 6, panel B shows a 2-fold increase of the TRH precursor 
mRNA and peptide only in the group stimulated with AngII with an intact TRH 
system compared to the culture cells with the specific TRH inhibition by siRNA-
TRH, in which TRH peptide levels were not different from that of control cells. As 
expected, TRH increase induce hypertrophic markers expression as seen in Figure 
6 panel C, where the  increases of TGF-β1 and BNP were only evident after AngII 
stimulus in the cells where the TRH system was active. Furthermore, the group 
stimulated with AngII with the TRH system suppressed was similar to the cells 
receiving saline with or without native TRH system active. A similar pattern was 
observed with the measurement of α-actin expression, a sarcomeric protein 
strongly related to hypertrophy, which was increased by AngII stimulus only in the 
group carrying a working TRH system.  
 
4. Discussion 
In this study, we propose the cardiac TRH as a common mediator in the 
development of the LVH, in particular in the AngII-induced hypertrophy. This work 
shows that AngII stimulates cardiac TRH and that TRH inhibition attenuates fibrotic 
and hypertrophic effects induced by AngII, thus making the cardiac TRH system a 
promising therapeutic target. 
Therefore, we treated C57BL/6 mice with saline, as a control and AngII to induce 
cardiac hypertrophy with and without a specific siRNA inhibition of the TRH 
system. We found that AngII definitely stimulates cardiac TRH. This stimulus was 
shown to be time-dependent, as we observed that the TRH increase after 7 days of 
AngII infusion was significantly lower than the one observed after 14 days of Ang II 
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infusion. As a result, cardiac TRH exerted pro-hypertrophic and pro-fibrotic cardiac 
effects. It is remarkable that in the short protocol where the TRH increase was mild 
and close to 50% above to that observed in controls, the increases in hypertrophy 
and fibrosis markers were also mild. Accordingly, we did not find macroscopic 
hypertrophy as the hypertrophic index was not different compared to controls, 
revealing that these gene alterations were just the beginning of the process. 
However, after 14 days of AngII infusion, there was a significant TRH increase 
confirmed by western blot and immunohystochemistry that brought about marked 
increases in hypertrophic and fibrotic markers. In this scenario, we found a 
significant increase in the hypertrophy index, indicating a well established 
hypertrophy induced by AngII only in the group with a functional TRH system. 
These findings reinforce the concept of an important role of TRH in LVH 
development.  
We found that increases in TRH gene expression were not reflected in precursor 
protein levels, probably due to a rapid processing of the preTRH to the tri-peptide 
which brings out the observed effects. Indeed we found an increase of more than 3 
fold in the expression of PC1 convertase, which process pro-TRH to cryptic 
peptides (data not shown); although, we cannot dismiss that the TRH precursor is 
secreted from the cell. Western blot results (TRH precursor and TGF-β1) were as 
not strong as immunohystochemistry results although, were confirmatory of the 
effect directions. Probably this quantitative discrepancy could be due to differences 
in the antibody used for each technique. Nevertheless, assuming that TRH 
inhibition was not completely achieved, it can be speculate that with a stronger 
inhibition, the effects observed could be totally prevented.  
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 As a whole, our results indicate that there is a positive correlation between LV 
TRH and hypertrophy/fibrotic markers, in which exposure time to the insult (in this 
study AngII) is a central issue. 
Our results highlight the relevance of the cardiac TRH system under pathological 
situations as no changes have been observed between animals receiving saline 
with an active or suppressed TRH gene expression.  
Decreases in TRH by 50%-70% were efficient to attenuate strongly fibrosis and 
also hypertrophy which suggest a threshold over which TRH participates actively in 
the development of this pathology. 
Furthermore, we showed that cardiac TRH is located downstream to AngII in the 
LVH development and point out the relevance of the TRH system in situations 
where the renin–angiotensin system is enhanced. It has been described by Bacova 
et al [13] that the transgenic rat model (mRen2) with an extra copy of the mouse 
renin 2 gene, which induces higher Ang II levels in both plasma and heart, 
increased the preTRH gene expression in the left ventricle. Related to our work, 
preTRH gene expression has been shown to be induced in the left ventricle of rats 
after myocardial infarction [14]  where, AngII  is overexpressed suggesting that 
maneuvers directed to modulate the cardiac AngII system would probably affect 
the TRH system in the heart.  Indeed, TRH can increase cardiac performance in 
rats with ischaemic cardiomyopathy [6]. 
On the contrary, Jin et al described that an early treatment with ACE inhibitors 
normalized many genes found to be increased in heart failure [6], but 
unexpectedly, the expression of preTRH in left ventricle is increased.  Whether this 
increase represents compensatory mechanism with detrimental effects remains to 
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be studied, even so we speculate that the inhibiting of TRH may be a useful 
therapeutic approach. 
The TRH induction evoked by AngII is evident in cardiac fibroblasts and 
cardiomyocytes, the two major cell components of the heart. Even more, both 
types of cells express the Ang II type 1 receptor [13], in addition to the specific 
TRH type I receptor and all the machinery necessary to express TRH as was 
reported previously [14,6]. Indeed, we have described previously that TRH 
overexpression was able to induce hypertrophic and fibrotic markers in rat primary 
cell culture of both myocytes and fibroblasts [5]. In line with those results, using 
validated models of  myocytes (H9C2) and fibroblasts (NIH 3T3) we were able to 
show that AngII induce an increase of TRH and a significant increase of 
hypertrophic markers, (BNP, β-MHC and TGF-β1), and expansion of ECM in both 
cell types. Furthermore, when TRH system is disrupted, the AngII effects were not 
observed, pointing out that TRH is an important mediator of AngII action in both 
cell types. We observed that although the tripeptide increase by 
immunofluorescence was similar in both type of cells, RNA expression was higher 
in fibroblasts probably due to differences in translation, traduction or processing. In 
myocytes, we found a mild 2-fold TRH increase compared to control, which was 
able to induce changes of the same magnitude on the hypertrophic markers, 
reinforcing the concept that higher levels of TRH implies higher damage to cardiac 
tissue.  
It is known that neonate cells could respond in a different way compared to adult 
cardiac cells, and we know the limitations on working on a cell line.  Nevertheless, 
cell culture results confirmed an Ang II-induced TRH action on cardiac cells. 
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Finally, we have tested “in vitro” our hypothesis that the TRH system is essential 
for the cardiac remodeling induced by AngII independently of any cardiovascular 
effect.  
It has to be mentioned that using rat heart slices Ang II significantly inhibited the 
secretion of TRH 13, which may explain partially our results as in this study we 
assessed TRH cell content. We think that “in vitro” results strongly support the “in 
vivo” observations and point out that cardiac TRH  mediates AngII cardiac effects.  
It is tempting to postulate the heart TRH system as a therapeutic target in cardiac 
hypertrophy. In fact, our siRNA-TRH performed well as a long-lasting inhibitory 
agent. 
Further investigations will be needed to elucidate the transduction signal pathways 
activated by TRH in heart tissue, so cardiac TRH is a novel mediator, perhaps a 
crucial step, in the cardiac effects induced by AngII and possibly other insults. 
 
4.1 Perspectives 
Our results put in evidence the role of the cardiac TRH system in heart 
pathophysiology especially in the disorders that involve the induction of AngII given 
that cardiac TRH acts like an AngII mediator. 
We have shown a siRNA designed against TRH which seems to be an effective 
strategy to knockdown the TRH system of the left ventricle that hinders the 
development of fibrosis and hypertrophy induced by AngII, opening the possibility 
of the management of the TRH system in situations in which the system is 
overexpressed. 
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Figure Legends: 
Figure 1:  Ang II treatment on systolic arterial blood pressure, daily water 
intake and body weight. 
Effects of the Ang II treatment (2mg/kg/day) in mice on systolic arterial blood 
pressure (SABP) (A), daily water intake (B) and body weight (C) compared with 
basal period (n=8/group). C57 adult mice were intracardiacally injected with siRNA-
Con or siRNA-TRH previously to AngII infusion compared with their basal. Results 
are expressed as media+SE. ANOVA *p<0.05, compared to basal group (n=8). 
 
 
Figure 2: Effect of 7-days Ang II infusion on left ventricular TRH and 
hypertrophic and fibrotic markers expression.  
Panel A shows left ventricle TRH precursor (pre-proTRH). In panel B and C, gene 
expression of type III collagen and   βMHC and brain natriuretic peptide (BNP) are 
shown as fibrotic and hypertrophic markers. Gene expression was determined by 
real-time PCR and normalized by ß-actin expression. C57 adult mice that were 
intracardiacally injected with siRNA-Con or siRNA-TRH previously to 7 days AngII 
infusion (2 mg/kg/day) compared with their control receiving saline (n=12/group). 
Results are expressed as percentage of control group. ANOVA *p<0.05, compared 
with saline group. 
 
Figure 3: Long-term Ang II infusion requires an intact left ventricle TRH 
system to induces LVH 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
Hypertrophy index  and cardiomyocytes diameter (panel A), left ventricle TRH 
precursor, mRNA expression and peptide, (panel B) ;  βMHC  and  BNP genes 
expression (panel C), TGF-β1 gene expression and protein  (panel D) and types III 
and I collagen gene expression (panel E) of C57 adult mice that were intracardiacly 
injected with siRNA-Con or siRNA-TRH previously to a long 14-day AngII infusion 
(2 mg/kg/day) compared with their control receiving saline (n=12/group). Genes 
expression was determined by real-time PCR normalized by ß-actin. Quantization 
of the TRH precursor and TGF- β1 protein was done  by western blot. Results are 
expressed as percentage of control group. ANOVA *p<0.05, compared with saline 
group. 
 
Figure 4: The long-term AngII infusion induces increases of TGF-β1, collagen 
type I and expansion of the ECM, all avoided by the left ventricular TRH 
inhibition.  
Effect of left ventricle TRH inhibition on ECM expansion in mice treated with 14 
days AngII infusion (2mg/kg/day). TRH and TGF-β proteins expression (panel A) 
and ECM expansion by Siriud Red staining and collagen type I (panel B). Note 
significant difference in ECM expansion (arrows) between groups (Masson’s 
Trichrome). Arrows indicate areas with different degree of fibrosis (left) and positive 
immunostaining for collagen type I (right) in both AngII-treated groups, (n=5). 
Tables represent the quantification of TRH and TGF-β proteins and ECM 
expansion areas in all groups. Results are expressed as mean + SD. ANOVA 
*p<0.05, compared with saline group; #p<0.05, versus AngII + siRNA-TRH. 
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Figure 5: An AngII stimulus induces the increase of TRH which act as a 
mediator of its fibrotic effects in fibroblasts NIH-3T3.   
Twenty-four hours AngII (1uM) induction on TRH protein content and TGF-β and 
collagen type I genes expressions, determined by immunofluorescence and real-
time PCR normalized by ß-actin expression, respectively, in NIH-3T3 cell culture 
(panel A), n=7. 
Effect of the TRH inhibition (siRNA transfection), on AngII  induction (1 µM, 24 h) 
over fibrotic markers in NIH-373 cell line. TRH-precursor, TGF-β and collagen type 
I genes expression determined by real-time PCR normalized by ß-actin expression 
(panel B).  Effect of losartan, (LST, 10 µM 30 min. before stimulus), on the 
induction of TRH and TGF-β genes expression by AngII (1uM). Results are 
expressed as percentage of control group. ANOVA *p<0.05, compared with control 
group, n=7. 
 
Figure 6: TRH mediates the hypertrophic effect of the AngII in H9C2 myocyte 
cell line.  
Effect of TRH inhibition (siRNA transfection), on AngII induction (1µM, 24 h) over 
hypertrophic markers in myocytes H9C2 cell line. TRH precursor RNA, TRH 
peptide (panel A), TGF-β and BNP (panel B) genes expression determined by 
immunofluorescence and real-time PCR normalized by ß-actin expression, 
respectively. Results are expressed as percentage of control group. ANOVA 
*p<0.05, compared with control group, n=7. 
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Highlights 
 TRH is a crucial step in the cardiac effects induced by AngII 
 In NH3T3 and H9C2 the AngII requires TRH to induce fibrotic and hypertrophic 
markers. 
 TRH-siRNA is an effective strategy to impede fibrosis/ hypertrophy induced by 
AngII 
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